Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Rattachement africain : us, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
PURPOSE: As immune checkpoint inhibitors (ICI) become increasingly used in frontline settings, identifying early indicators of response is needed. Recent studies suggest a role for circulating tumor DNA (ctDNA) in monitoring response to ICI, but uncertainty exists in the generalizability of these studies. Here, the role of ctDNA for monitoring response to ICI is assessed through a standardized approach by assessing clinical trial data from five independent studies. PATIENTS AND METHODS: Patient-level clinical and ctDNA data were pooled and harmonized from 200 patients across five independent clinical trials investigating the treatment of patients with non-small-cell lung cancer with programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1)-directed monotherapy or in combination with chemotherapy. CtDNA levels were measured using different ctDNA assays across the studies. Maximum variant allele frequencies were calculated using all somatic tumor-derived variants in each unique patient sample to correlate ctDNA changes with overall survival (OS) and progression-free survival (PFS). RESULTS: < .001). Changes in the maximum variant allele frequencies ctDNA values showed strong association across different outcomes. CONCLUSION: In this pooled analysis of five independent clinical trials, consistent and robust associations between reductions in ctDNA and outcomes were found across multiple end points assessed in patients with non-small-cell lung cancer treated with an ICI. Additional tumor types, stages, and drug classes should be included in future analyses to further validate this. CtDNA may serve as an important tool in clinical development and an early indicator of treatment benefit.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
- Date Crossref
- 01/07/2022
- Éditeur
- American Society of Clinical Oncology (ASCO)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Friends of Cancer Research pays non établi dans la noticeOrganisation à but non lucratif
-
Cancer Research And Biostatistics pays non établi dans la noticeOrganisation à but non lucratif
-
University of Pennsylvania Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center pays non établi dans la noticeUniversité ou école supérieure
-
Sidney Kimmel Comprehensive Cancer Center pays non établi dans la noticeStructure de recherche
-
Bristol-Myers Squibb (United States) pays non établi dans la noticeEntreprise
-
United States Food and Drug Administration pays non établi dans la noticeOrganisme public
-
Washington University in St. Louis Department of Computer Science and Engineering pays non établi dans la noticeUniversité ou école supérieure
-
Guardant (United States) pays non établi dans la noticeEntreprise
-
Foundation Medicine (United States) pays non établi dans la noticeEntreprise
-
AstraZeneca (United Kingdom) pays non établi dans la noticeEntreprise
-
AstraZeneca (United States) pays non établi dans la noticeEntreprise
Friends of Cancer Research, Cancer Research And Biostatistics et Department of Medicine — University of Pennsylvania, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.